People · Operator
Named in public records as an officer, director or promoter · active 2008–2012 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gen9, Inc. | — | Biotechnology | Series B | $52.1M | $992.2M | 2011 |
| Nodal Exchange, Llc | — | Other | Series B | $46.4M | $438.6M | 2008 |
Lawrence Silverstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lawrence Silverstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Stone | 1 | 12 |
| Paul Manning | 1 | 6 |
| Stanley Rose | 1 | 4 |
| Jeremy Wertheimer | 1 | 4 |
| James P. Smist | 1 | 4 |
| Joseph Jacobson | 1 | 3 |
| Weili Dai | 1 | 3 |
| Stephen Jurvetson | 1 | 2 |
| George Church | 1 | 2 |
| Aaron Zucker | 1 | 2 |
| Benjamin Preston | 1 | 2 |
| Martin Goldberg | 1 | 1 |
| Wali Dai | 1 | 1 |
| Robert J.S. Roriston | 1 | 1 |
| Paul J. Cusenza | 1 | 1 |
| Dean L. Wilde, II | 1 | 1 |
| Mark Maisto | 1 | 1 |
| Andrew J. Stevens | 1 | 1 |
| Ann Sacra | 1 | 1 |
| Drew Endy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.